

## Machine Learning and Prediction of Antimicrobial Resistance (AMR)

Sam Zhu 4<sup>th</sup> year Ph.D. student Supervisor: Professor Margaret IP Joint Graduate Seminar Department of Microbiology 13<sup>th</sup> December 2018

### Outline

- Burden and introduction of AMR
- From genotype to phenotype
- Application of machine learning

#### Potential routes of transmission of AMR bacteria



## Death attribute to AMR



#### Research & Development in antibiotics



#### **A PERFECT STORM**

As bacterial infections grow more resistant to antibiotics, companies are pulling out of antibiotics research and fewer new antibiotics are being approved.



\*Proportion of clinical isolates that are resistant to antibiotic. MRSA, methicillin-resistant Staphylococcus aureus. VRE, vancomycin-resistant *Enterococcus*. FQRP, fluoroquinolone-resistant *Pseudomonas aeruginosa*.



## Rapid diagnostics to optimise treatment

Machine learning application in dermatology, histopathology images



#### Antimicrobial Susceptibility Test: Methods

1. Broth Dilution





Phoenix

2. Antimicrobial gradient diffusion, disk diffusion test



3. Automated instrument systems



Vitek 2



#### Sensititre ARIS 2X

#### Antimicrobial Susceptibility Test: Criteria





Interpretive criteria by CLSI/EUCAST based on:

- (1) microbiologic data
- (2) pharmacokinetic and pharmacodynamic data (PK/PD)
- (3) Clinical study results

Sensitive(S) Intermediate(I) Resistant(R)

#### Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems



Performance:

1. Essential Agreement (EA): > 90%

exact agreement or within ± one two - fold dilution of the reference method

2. Discrepancy – major:  $\leq 3\%$ 

The reference category result is S and the new device result is R.

3. Discrepancy – very major: based on population

The reference category result is R and the new device result is S.

| Acceptable<br>Number of<br>Discrepancies | Estimated<br>Rate <sup>a</sup>  | 95% Confidence<br>Interval <sup>b</sup> for True VMJ<br>Rate   |
|--|---|--|
| 0  | 0.00  | (0.00, 7.40)   |
| 0  | 0.00  | (0.00, 7.11)   |
| 0  | 0.00  | (0.00, 5.96)   |
| 0  | 0.00  | (0.00, 5.13)   |
| 1  | 1.39  | (0.04, 7.50)   |
| 1  | 1.25  | (0.03, 6.77)   |
| 1  | 1.11  | (0.03, 6.04)   |
| 2  | 2.13  | (0.26, 7.48)   |
| 2  | 2.00  | (0.24, 7.04)   |
| 2  | 1.82  | (0.22, 6.41)   |
| 3  | 2.50  | (0.52, 7.13)   |
| 3  | 2.31  | (0.48, 6.60)   |
| 4  | 2.86  | (0.78, 7.15)   |
|  | Acceptable<br>Number of<br>Discrepancies<br>0<br>0<br>0<br>0<br>1<br>1<br>1<br>1<br>2<br>2<br>2<br>2<br>3<br>3<br>4 | Acceptable<br>Number of<br>Discrepancies   Estimated<br>Rate <sup>a</sup> 0   0.00     0   0.00     0   0.00     0   0.00     0   0.00     0   0.00     1   1.39     1   1.25     1   1.11     2   2.13     2   2.00     2   1.82     3   2.50     3   2.31     4   2.86 |



#### Cost per Raw Megabase of DNA Sequence

Number of bacterial and archaeal genomes sequenced each year and submitted to NCBI.



Land, 2015

# Susceptible or Resistant based on presence and absence of AMR genes

| Year | Bacteria              | Model | Antibiotics | EA  | ME   | VME  |
|------|-----------------------|-------|-------------|-----|------|------|
| 2013 | 74 E. coli<br>69 Kpne | -     | 7           | 96% | 2.1% | 1.2% |

| Species | Antibiotics (ME)     | Genotype            | Phenotype | Spe | cies | Antibiotics (VME)              | Genotype | Phenotype      |
|---------|----------------------|---------------------|-----------|-----|------|--------------------------------|----------|----------------|
| E. coli | Ceftazidime<br>(15%) | blaTEM,<br>blaCTX-M | S         | Kpn | e    | Ciprofloxacin (6%)             | -        | R              |
| Крпе    | Amoxicillin<br>(4%)  | blaSHV              | S         |     |      | EA: essential agreement >>>R ≤ |          | <u>&gt;90%</u> |
|         |                      |                     |           |     |      |                                |          | ≤ 3%           |

Others: S. aureus, MTB, Nontyphoidal Salmonella...

< 3%

VME: very major error R->S

| Minimum Inhibitory concentration (MIC) |      |     |   |   |   |   |    |    |    |
|--|------|-----|---|---|---|---|----|----|----|
| 0.12                                   | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 |

#### How to predict exact value?

#### Supervised leaning in Machine Learning



# Minimum Inhibitory concentration (MIC) Prediction by machine learning methods

| Year | Species                  | Model                                       | Target              | Total | EA  | ME   | VME  |
|------|--------------------------|---|---------------------|-------|-----|------|------|
| 2017 | pneumococcu<br>s         | Random forest                               | 3 PBP<br>types      | 4309  | 97% | 1.2% | 1.4% |
| 2017 | Neisseria<br>gonorrhoeae | Multivariate<br>linear regression<br>models | ~10<br>AMR<br>genes | 681   | 93% | 1.3% | 1.7% |

| EA: essential agreement    | >90% |
|----------------------------|------|
| ME: major error S->R       | ≤ 3% |
| VME: very major error R->S | < 3% |

## Can We Use Whole Genome Data Without A Priori Information?

#### K-mer based modelling



| MATRIX  | MIC | ΑΑΑΑΤΤΤΤΟ | AAAATTTTCG |  |  |  |
|---------|-----|-----------|------------|--|--|--|
| sample1 | 4   | 20        | 30         |  |  |  |
| sample2 | 8   | 10        | 20         |  |  |  |
|         |     |           |            |  |  |  |
|         |     |           |            |  |  |  |

XGBoost (Extreme Gradient Boosting) model



### K-mer based modelling (1)

| Year | Species                  | Model   | Target          | Total | EA  | ME   | VME  |
|------|--------------------------|---------|-----------------|-------|-----|------|------|
| 2017 | Klebsiella<br>pneumoniae | XGBoost | Whole<br>genome | 1668  | 92% | 3.7% | 3.1% |

Requires no *a priori* knowledge

EA is largely dependent on the number of resistant isolates that were sampled for each antibiotic

EA is similar (92%) of 3 models: Whole genome data & AMR genes & Non-AMR genes

### K-mer based modelling (2)

| Year | Species                           | Model   | Target          | Total | EA  | ME   | VME  |
|------|-----------------------------------|---------|-----------------|-------|-----|------|------|
| 2018 | Nontyphoidal<br><i>Salmonella</i> | XGBoost | Whole<br>genome | 5278  | 95% | 2.7% | 0.1% |



4500 genomes due to memory limit (1.5TB)

Nguyen, 2018

#### EA is stable by year, source, states

| Collection Date | Accuracy |
|-----------------|----------|
| 2002            | 0.97     |
| 2003            | 0.95     |
| 2004            | 0.96     |
| 2005            | 0.95     |
| 2006            | 0.95     |
| 2007            | 0.94     |
| 2008            | 0.95     |
| 2009            | 0.95     |
| 2010            | 0.94     |
| 2011            | 0.95     |
| 2012            | 0.96     |
| 2013            | 0.97     |
| 2014            | 0.95     |
| 2015            | 0.95     |
| 2016            | 0.96     |

| Source   | Accuracy |
|----------|----------|
| Chicken  | 0.96     |
| Cow/Beef | 0.94     |
| Pig/Pork | 0.95     |
| Turkey   | 0.94     |



| Training  | Test set  |          |
|-----------|-----------|----------|
| set years | years     | Accuracy |
| 2002-2008 | 2009-2016 | 0.88     |
| 2002-2009 | 2010-2016 | 0.88     |
| 2002-2010 | 2011-2016 | 0.88     |
| 2002-2011 | 2012-2016 | 0.88     |
| 2002-2012 | 2013-2016 | 0.88     |
| 2002-2013 | 2014-2016 | 0.86     |
| 2002-2014 | 2015-2016 | 0.92     |

#### XGBoost assigns important k-mers predict MIC change

| Table 6. The highest-ranking AMR-related protein function (or genomic region) with a matching k-mer from the XGBoost models. |      |                           |                  |   |  |  |  |  |  |
|--|------|---------------------------|------------------|---|--|--|--|--|--|
|  | К-   | Distance                  |                  |   |  |  |  |  |  |
|  | mer  | between k-mer             |                  |   |  |  |  |  |  |
| Antibiotic   | Rank | and AMR gene <sup>1</sup> | k-mer            | PATRIC Annotation(s)  |  |  |  |  |  |
| AMP  | 1    | Direct match              | CTTAATCAGTGAGGC  | Class A beta-lactamase (EC 3.5.2.6) => TEM family               |  |  |  |  |  |
| AUG  | 1    | Direct match              | AAACGTCTTACTAAC  | Class C beta-lactamase (EC 3.5.2.6) => CMY/CMY-2/CFE/LAT family |  |  |  |  |  |
| AXO <sup>2</sup>   | 1    | 566.0 ± 39.7              | AAAGAGAAAAGAAAGG | Class C beta-lactamase (EC 3.5.2.6) => CMY/CMY-2/CFE/LAT family |  |  |  |  |  |
| AZI  | 8    | Direct match              | CCCATTTCCGCCGCC  | Macrolide 2'-phosphotransferase => Mph(A) family                |  |  |  |  |  |
|  |      |                           |                  | Chloramphenicol/florfenicol resistance, MFS efflux pump => FloR |  |  |  |  |  |
| CHL <sup>2</sup>   | 1    | 611.8 ± 5.1               | AGACAAGTAAGCCGC  | family  |  |  |  |  |  |
|  |      |                           |                  | Pentapeptide repeat protein QnrB family => Quinolone resistance |  |  |  |  |  |
| CIP  | 1    | 313.5 ± 70.5              | ACAGTCCATCCAGGA  | protein QnrB10  |  |  |  |  |  |

Table 7. Important k-mers used by the individual antibiotic models for predicting susceptible MICs.

|            |                 |                  |                  | Frac             | Frac             | Genomic             |  |
|------------|-----------------|------------------|------------------|------------------|------------------|---------------------|--|
| Antibiotic | k-mer           | Sus <sup>1</sup> | Res <sup>1</sup> | Sus <sup>2</sup> | Res <sup>2</sup> | region <sup>3</sup> | PATRIC annotation or genomic region              |
| NAL        | ATTCCGCAGTGTATG | 5233             | 45               | 1.00             | 0.38             | PEG                 | DNA gyrase subunit A (EC 5.99.1.3)               |
| AXO        | TGGTATTCGCATCAA | 4508             | 769              | 0.78             | 0.48             | PEG                 | Phosphoethanolamine transferase EptA             |
| KAN        | CTGGCTTTTTTTT   | 837              | 84               | 0.30             | 0.00             | RNA                 | RyhB RNA   |
| STR        |                 |                  |                  |                  |                  |                     | Respiratory nitrate reductase delta chain (EC    |
|            | CCCTTATCCAACACG | 872              | 1919             | 0.85             | 0.55             | PEG                 | 1.7.99.4)  |
|            |                 |                  |                  |                  |                  |                     | Formate-dependent nitrite reductase complex      |
| AXO        |                 |                  |                  |                  |                  |                     | subunit NrfF, and Cytochrome c-type heme lyase   |
|            | CAGAACCAGAATTTG | 4508             | 769              | 0.74             | 0.46             | PEGs                | subunit nrfE, nitrite reductase complex assembly |

#### Conclusions

- Whole genome sequencing offers the potential in predicting AMR
- Machine learning algorithms demonstrate value in MIC prediction with acceptable accuracy in clinical diagnosis
- XGBoost is readily to be applied to other important human pathogens even without *a priori* AMR information

#### Limitation

- Training set: large, balanced database with metadata
- Interpretation: Machine learning models exhibit a trade-off between accuracy and intelligibility

## Reference (1)

- Jim O'Neill . *Tackling drug-resistant infections globally: final report and recommendations*. Review on Antimicrobial Resistance, 2016.
- Cooper, Matthew A., and David Shlaes. "Fix the antibiotics pipeline." *Nature* 472.7341 (2011): 32.
- Esteva, Andre, et al. "Dermatologist-level classification of skin cancer with deep neural networks." *Nature* 542.7639 (2017): 115.
- Bychkov, Dmitrii, et al. "Deep learning based tissue analysis predicts outcome in colorectal cancer." Scientific reports 8.1 (2018): 3395.
- US Food and Drug Administration. "Class II special controls guidance document: antimicrobial susceptibility test (AST) systems." *Food and Drug Administration, Silver Spring, MD*(2009).
- Land, Miriam, et al. "Insights from 20 years of bacterial genome sequencing." *Functional & integrative genomics* 15.2 (2015): 141-161.
- Stoesser, N., et al. "Predicting antimicrobial susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic sequence data." *Journal of Antimicrobial Chemotherapy* 68.10 (2013): 2234-2244.
- Bradley, Phelim, et al. "Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis." *Nature communications* 6 (2015): 10063.
- Gordon, N. C., et al. "Prediction of Staphylococcus aureus antimicrobial resistance from whole genome sequencing." *Journal of clinical microbiology* (2014): JCM-03117.

## Reference (2)

- McDermott, Patrick F., et al. "The use of whole genome sequencing for detecting antimicrobial resistance in nontyphoidal Salmonella." *Antimicrobial agents and chemotherapy* (2016): AAC-01030.
- Li, Yuan, et al. "Validation of β-lactam minimum inhibitory concentration predictions for pneumococcal isolates with newly encountered penicillin binding protein (PBP) sequences." BMC genomics 18.1 (2017): 621.
- Eyre, David W., et al. "WGS to predict antibiotic MICs for Neisseria gonorrhoeae." *Journal of Antimicrobial Chemotherapy* 72.7 (2017): 1937-1947.
- Chen, Tianqi, and Carlos Guestrin. "Xgboost: A scalable tree boosting system." *Proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining*. ACM, 2016.
- Nguyen, Marcus, et al. "Developing an in silico minimum inhibitory concentration panel test for Klebsiella pneumoniae." *Scientific reports* 8.1 (2018): 421.
- Nguyen, Marcus, et al. "Using machine learning to predict antimicrobial minimum inhibitory concentrations and associated genomic features for nontyphoidal Salmonella." (2018): *JCM* 01260-18.

## Thank you